Dopamine receptors--physiological understanding to therapeutic intervention potential.
about
Activation of dopamine D4 receptors by ABT-724 induces penile erection in ratsMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesInvolvement of dopamine D2 receptors in addictive-like behaviour for acetaldehydeParkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresisIdentification of human dopamine D1-like receptor agonist using a cell-based functional assay.Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.A new approach for structure analysis of two-dimensional membrane protein crystals using X-ray powder diffraction data.Adult attention deficit hyperactivity disorder is associated with asthma.Pharmacology of signaling induced by dopamine D(1)-like receptor activationFurther delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders.Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studiesPrenatal ethanol exposure alters synaptic plasticity in the dorsolateral striatum of rat offspring via changing the reactivity of dopamine receptor.A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants.Dopamine and serotonin receptor binding and antipsychotic efficacy.Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior.Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.Adult attention deficit hyperactivity disorder is associated with migraine headaches.Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.Dopamine receptor microdomains involved in molecular recognition and the regulation of drug affinity and function.Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern MonitorDopamine receptor antagonism disrupts social preference in zebrafish: a strain comparison study.The influence of five monoamine genes on trajectories of depressive symptoms across adolescence and young adulthood.Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinCholinergic connectivity: it's implications for psychiatric disorders.A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons.Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptorsGenetic Contribution of Catechol-O-methyltransferase Polymorphism in Patients with Migraine without Aura.Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.Thyroid hormone and adrenergic signaling interact to control pineal expression of the dopamine receptor D4 gene (Drd4).Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration.Challenges in understanding the impact of blood pressure management on cerebral oxygenation in the preterm brainRisk of heart failure following treatment with dopamine agonists in Parkinson's disease patients.Insight into the mechanism of dopamine D1-like receptor activation. Evidence for a molecular interplay between the third extracellular loop and the cytoplasmic tail.Headache and ADHD in Pediatric Age: Possible Physiopathological Links.Considerations for ADHD in the child with epilepsy and the child with migraine.[Acute treatment of migraine in emergency room: comparative study between dexametasone and haloperidol. Preliminary results].Parkinson's disease: genetics and beyond.
P2860
Q24564691-AC9021AC-283C-406D-B9A8-54AAC15B02F8Q28066691-69507245-46C3-4F21-BFB2-27670645FC8DQ28539688-71450FC0-AE23-483C-9DF9-3896FF5FA2BFQ28833697-6B17D3F3-31B1-4535-A5E3-91059D94AE77Q30863631-C881F96F-2900-4D68-9D66-44F64BFDA739Q33639920-99FCCAB3-0173-4079-87E1-734296D3661BQ33770771-923943C4-9ACD-4A8C-ABCE-EDC8DF859724Q33984093-14232F12-EB27-4A80-B6F7-A61EDF332E80Q34126949-3861090C-B2E2-47E7-B1BD-EEB0D4C7E636Q34129968-4C83ABC0-A446-45D4-8EC0-66596E34B82CQ34174978-E3610ECD-4C1D-4DA0-9F9A-F476753EA46EQ34348803-1847C4B3-5B06-4EB0-BCEA-DF20EBBCAFBDQ34390849-268ED01E-8B1D-4A81-BC71-333233EF4ADFQ34394954-71A4C422-6C6D-48D2-A9FE-CFB37B510EC7Q34605995-83687737-C044-4D4B-A7DF-1B9E52BA90F9Q34631580-47E35301-45AA-46C7-B9F4-25FA4CAF33FAQ35166725-4CAF31B7-BC30-40DC-8772-62EC496BECAEQ35577398-2CDAB8E0-AF58-4A52-ADF1-EB2FB809CA97Q35805941-5492CDC0-3AD3-49EC-8259-3FAADD4E1D34Q35936722-F4294B68-66AE-4025-A015-126FAE49D770Q36067222-4B74E475-74F7-4BCE-9C92-120EEE9EA4E4Q36069708-6D95C5E4-F374-45A9-88D2-5B0C8A78FC04Q36183407-32950AC5-F045-4FC9-A64C-3A02A5F2659AQ36448838-604D3660-958F-49D7-B2BF-1117CA57185DQ36575989-9D2E533D-019F-4D50-A0B5-28DC3DDC97AFQ36812599-19A717AB-49F0-4945-80E3-606E75B76255Q36901123-771AE1B7-AA27-4430-834D-9EDCBB0421D6Q37023517-D2A25382-12D0-48F6-9629-C0A7041B225FQ37140503-0C9D11F3-C237-4A12-9C99-B15A6ED485AEQ37203501-4147F5BF-07F4-439B-AD00-12D006618BE1Q37239341-1A71865C-FB85-429C-88E5-293ADC561639Q37438782-6031E815-7CCE-4B5E-A199-14CA15C0ED51Q37772934-76848F34-30DA-48FD-87D6-08BE014FAB77Q38069574-15D6D01C-FB77-411D-832E-8C0F683F2BBFQ38189113-1FF47A47-5B4F-4C61-91D9-3D8B288903EFQ38359032-AC16FE28-A3D4-4EB5-8F81-9911ED02B057Q38518304-DD070F24-0D50-4507-A4D6-C57C8F26B438Q38658017-79435330-1E4C-419D-9C8D-1A9C39B194BBQ39378038-562721F3-A504-4AB7-B453-555BCDA52774Q39416222-3EF0CB2F-86C1-4461-ACB6-7A16706ADA37
P2860
Dopamine receptors--physiological understanding to therapeutic intervention potential.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Dopamine receptors--physiological understanding to therapeutic intervention potential.
@ast
Dopamine receptors--physiological understanding to therapeutic intervention potential.
@en
type
label
Dopamine receptors--physiological understanding to therapeutic intervention potential.
@ast
Dopamine receptors--physiological understanding to therapeutic intervention potential.
@en
prefLabel
Dopamine receptors--physiological understanding to therapeutic intervention potential.
@ast
Dopamine receptors--physiological understanding to therapeutic intervention potential.
@en
P2093
P1476
Dopamine receptors--physiological understanding to therapeutic intervention potential.
@en
P2093
P304
P356
10.1016/S0163-7258(99)00029-7
P577
1999-11-01T00:00:00Z